Halozyme Therapeutics, Inc. (LON: 0J2O)

Market Cap	5.71B
Revenue (ttm)	706.82M
Net Income (ttm)	292.82M
Shares Out	n/a
EPS (ttm)	2.26
PE Ratio	19.50
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,230
Average Volume	1,765
Open	55.56
Previous Close	55.46
Day's Range	55.01 - 55.99
52-Week Range	30.09 - 55.99
Beta	n/a
RSI	67.75
Earnings Date	Feb 20, 2025

About Halozyme Therapeutics

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1998
• Employees: 373
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0J2O

Financial Performance

In 2023, Halozyme Therapeutics's revenue was $829.25 million, an increase of 25.62% compared to the previous year's $660.12 million. Earnings were $281.59 million, an increase of 39.31%.

Financial numbers in USD